• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Invanz (ertapenem) injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

July 2013

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • depressed level of consciousness

 

December 2009

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • includes altered mental status (including aggression, delirium), dyskinesia, myoclonus, and tremor